Floatz logo

Factor Viii Inhibitor Bypassing Fraction

Hemophilia

Baxalta now part of ShiremixturePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Hemophilia cohort.

Asset / SponsorPhaseRating
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT
Chulalongkorn University
Phase 4BB
Stsp-0601 For
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3BB
Immunoglobulin G1, Anti-(Human Tissue Factor Pathway Inhibitor) (Human Monoclonal Pf-06741086 .Gamma.1-Chain), Disulfide With Human Monoclonal Pf-06741086 .Lambda.-Chain, Dimer
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Ribavirin
Kenneth Sherman
Phase 4BB
PEGYINTERFERON-ALFA-2A
Baqiyatallah Medical Sciences University
Phase 4BB

View all 32 →

Same molecule, other indications

Factor Viii Inhibitor Bypassing Fraction is also rated in:

hemophilia AActive
BBB
Indicative · Phase 4
72 / 100
View asset →
hemophilia BDormant
B
Indicative · Phase 3
60 / 100
View asset →
severe hemophilia ADormant
D
Indicative · N/A
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →